Online inquiry

IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2182MR)

This product GTTS-WQ2182MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000585.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3600
UniProt ID P40933
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2182MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6801MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ3210MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ11517MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ14999MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ15425MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ14275MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ2498MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ11364MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW